Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 2, 2021 (5 years ago)

Clopidogrel Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of foreign matter

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Clopidogrel Tablets, USP, 75 mg, 500-count bottle, Rx only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceutical Ltd., Baddi, Himachal, Pradesh, INDIA NDC 33342-060-15

Affected NDC 33342-0060-15

Compare with the code on your package — it is the most precise check available.

Drug: Clopidogrel

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Clopidogrel
NDC 33342-0060
BISULFATE 75 mg/1 Tablet
Oral
Macleods Pharmaceuticals Limited Rx
Recalling firm
Macleods Pharma Usa Inc
NDC code
33342-060-15
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0787-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Clopidogrel recalls

See all
Class II · Moderate risk

Clopidogrel Tablets USP

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8190-9 D-0513-2023
Class II · Moderate risk

Clopidogrel Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-218-10 D-0380-2023
Class II · Moderate risk

Clopidogrel Tablets

Failed dissolution specification -Two additional lots being recalled due to Out-of-Specification results observed for dissolution at 18th month stability testing.

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-671-31 D-0294-2019
Class II · Moderate risk

Clopidogrel Tablets

Failed Dissolution Specification: Out-of-Specification results were observed for dissolution at 18th month stability testing.

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-671-31 D-0283-2019
Class I · High risk

Clopidogrel Tablets

LABELING: LABEL MIX-UP. Simvastatin tablets, USP 10 mg were found in bottles labeled as Clopidogrel tablets, USP 75 mg.

Terminated Labeling / mix-up International Laboratories, LLC NDC 54458-888-16 D-0472-2018

Other recalls by Macleods Pharma Usa Inc

All 2021 recalls
Class III · Low risk

Levofloxacin Tablets

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Terminated Labeling / mix-up Macleods Pharma USA, INC NDC 33342-022-08 D-0162-2023
Class II · Moderate risk

Eszopiclone Tablets

Shortfill: customer complaints of one to three tablets were reported missing from 30 count bottles.

Terminated Failed specification Macleods Pharma Usa Inc NDC 33342-299-07 D-1174-2022